GnRH analogues in the treatment of endometriosis — rationale and efficacy

Endometriosis in the reproductive years has its peak incidence between 30 and 45 years as the continued growth of endometriotic tissue is dependent upon oestrogen. As has been outlined in other chapters in this book, the treatment of endometriosis depends upon the site, extent, symptoms of the disease, the patient’s age and her childbearing expectations. Thus treatment is tailored to individual needs. It may be broadly surgically based or a medical approach. Preview Unable to display preview. Download preview PDF. Similar content being viewed by others

Schally, A.V., Arimura, A., Baba, Y., Nair, R.M.G., Matsuo, H., Redding, T.W., Debdjuk, L. and White, W.F. (1971). Isolation and properties of the FSH and LH-releasing hormone. Biochem. Biophys. Res. Commun., 43, 393–399 Clayton, R.N. (1989). Cellular actions of gonadotrophin-releasing hormone: the receptor and beyond. In Shaw, R.W. and Marshall, J.C. (eds.) LHRH and its Analogues — Their Use in Gynaecological Practice, pp. 19–34. (London: Wright) Kiesel, L. and Runnebaum, B. (1990). Mechanisms involved in the hormonal treatment of endometriosis. In Chandha, D.R. and Buttram, V.C. (eds.) Current Concepts in Endometriosis, pp. 179–196. (New York: Alan R. Liss) Sandow, J. (1983). Clinical applications of LHRH and its analogues. Clin. Endocrinol., 18, 571–592 Meldrum, D.R., Chang, R.J., Lu, J., Vale, W., Rivier, J. and Judd, H.L. (1982). ’Medical oophorectomy’ using a long-acting GnRH agonist: a possible new approach to the treatment of endometriosis. J. Clin. Endocrinol Metab., 54, 1081–1083 Shaw, R.W., Fraser, H.M. and Boyle, H. (1983). Intranasal treatment with luteinizing hormone-releasing hormone agonist in women with endometriosis. Br. Med. J., 287, 1167–1169 Lemay, A., Maheux, R., Faure, N., Jean, C. and Fazekas, A. (1984). Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LHRH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil. Steril., 41, 863–871 Shaw, R.W. and Matta, W. (1986). Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis: comparison of two dose regimens. Clin. Reprod. Fertil., 4, 329–336 Schriock, E., Monroe, S.E., Henzl, M. and Jaffe, R.B. (1985). Treatment of endometriosis with a potent agonist of gonadotrophin releasing hormone (Nafarelin). Fertil. Steril., 44, 585–588 Steingold, K.A., Cedars, M., Lu, J.K.H., Rändle, R.N., Judd, H.L. and Meldrum, D.R. (1987). Treatment of endometriosis with a long-acting gonadotrophin-releasing hormone agonist. Obstet. Gynecol., 69, 403–411 Shaw, R.W. (1988). LHRH analogues in the treatment of endometriosis — comparative results with other treatments. Clin. Obstet. Gynaecol., 2, 659–675 Jelley, R.J. (1986). Multicentre open comparative study of buserelin and danazol in the treatment of endometriosis. Br. J. Clin. Pract., 41 (suppl. 48), 64–68 Shaw, R.W. (1990). Goserelin-depot preparation of LHRH analogue used in the treatment of endometriosis. In Chandha, D.R. and Buttram, V.C. (eds.) Current Concepts in Endometriosis. (New York: Alan R. Liss) Kiesel, L., Thomas, K., Tempore, A., Trabant, H., Widdra, W. and Runnebaum, B. (1989). Efficacy and safety of buserelin treatment in women with endometriosis — a multicentre open-label study. Gynaecol. Endocrinol., 3 (suppl. 2), 5–19 Matta, W.H. and Shaw, R.W. (1986). A comparative study between buserelin and danazol in the treatment of endometriosis. Br. J. Clin. Pract., 41 (suppl. 48), 69–73 Lemay, A. (1988). Comparison of GnRH analogues to conventional therapy in endometriosis. In International Symposium on GnRH Analogues, Geneva, Abstract 020 Dawood, M.Y., Spellacy, W.N., Dmowski, W.P., Gambrell, R.D., Greenblatt, R.B., Girard, Y., Lemay, A., Mishell, D.R., Nagamani, M., Pepperell, R.J., Shaw, R.W., Seibel, M.M., Sondheimer, S.J., Klioze, S.S., Schreider, J., Setescak, L. and Spiro, T. (1990). A comparison of the efficacy and safety of Buserelin vs Danazol in the treatment of endometriosis. In Chandha, D.R. and Buttram, V.C. (eds.) Current Concepts in Endometriosis (New York: Alan R. Liss) Henzl, M.R., Corson, S.L., Moghissi, K., Buttram, V.C, Bergqvist, C. and Jacobson, C. (1988). Administration of nasal nafarelin as compared with oral danazol for endometriosis. N. Engl. J. Med., 318, 455–489 Miller, J.D. (1990). Lenprolide acetate for the treatment of endometriosis. In Chandha, D.R. and Buttram, V.C. (eds.) Current Concepts in Endometriosis (New York: Alan R. Liss) Minaguchi, H., Vermura, T.L. and Shitzsu, K. (1989). Clinical study on finding the optimal dose of a potent LHRH agonist (Buserelin) for the treatment of endometriosis — multicentre trial in Japan. In Rolland, R., Chandha, D.R. and Willemsen A. (eds.) Gonadotrophin Down Regulation in Gynaecological Practice, pp. 211–225. (New York: Alan R. Liss) Crook, D., Gardner, R. and Worthington, M. (1989). Zoladex (ICI 118630) versus Danazol in the treatment of pelvic endometriosis: effects on plasma lipid risk factors. In Stoll, Basil A. (ed.) Proceedings of the International Symposium on Endocrine Therapy, pp. 157–160. (Basel: Karger) (Hormone Research, 32 (suppl. 1)) Matta, W.H., Shaw, R.W., Hesp, R. and Katz, D. (1987). Hypogonadism induced by luteinizing hormone-releasing hormone agonist analogues: effects on bone density in premenopausal women. Br. Med. J., 294, 1523–1524 Matta, W.H., Shaw, R.W., Hesp, R. and Evans, R. (1988). Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue Buserelin in premenopausal women. Clin. Endocrinol., 29, 45–51 Cann, C.E., Henzl, M., Burry, K. et al. (1986). Reversible bone loss is induced by GnRH agonists. In The Endocrine Society 68th Annual Meeting, Abstract 24 Devogelaer, J.P., Nagant de Deuxhcaisnes, C. and Donnez, J. (1987). LHRH analogues and bone loss. Lancet, 1, 1498 Scharia, S.H., Minne, H.W. and Waibel, S. (1988). GnRH agonist therapy alters calcium homeostasis and reduces bone mineral content. Acta Endocrinol., 117 (suppl. 287), 208 Tummon, L.S., Radwanska, E. and Ali, A. (1988). Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotrophin-releasing hormone agonists or danazol. Fertil. Steril., 49, 792–796 Stevenson, J.C, Lees, B., Gardner, R. and Shaw, R.W. (1989). A comparison of the skeletal effects of Zoladex and Danazol in premenopausal women with endometriosis. In Stoll, Basil A. (ed.) Proceedings of the International Symposium on Endocrine Therapy, pp. 161–164. (Basel: Karger) (Hormone Research, 32 (suppl. 1)) Stevenson, J.C, Lees, B. and Davenport, M. (1988). Determinants of bone density in normal women: risk factors for future osteoporosis? Br. Med. J., 298, 924–928 Editor information Editors and Affiliations Rights and permissions Copyright information © 1991 Springer Science+Business Media Dordrecht About this chapter Cite this chapter Shaw, R.W. (1991). GnRH analogues in the treatment of endometriosis — rationale and efficacy. In: Thomas, E.J., Rock, J.A. (eds) Modern Approaches to Endometriosis. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-3864-2_14 Download citation DOI: https://doi.org/10.1007/978-94-011-3864-2_14 Publisher Name: Springer, Dordrecht Print ISBN: 978-94-010-5719-6 Online ISBN: 978-94-011-3864-2 eBook Packages: Springer Book Archive

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.